US appeals court upholds West Virginia restriction on abortion pill sales
A three-judge panel of the 4th U.S. Circuit Court of Appeals in Richmond, Virginia, affirmed a ruling by a U.S. district judge in 2023 despite federal regulators' approval of the abortion pill as a safe and effective medication.
Most Republican-controlled states have enacted or adopted abortion bans of some kind, including restricting abortion pills by default, since the U.S. Supreme Court in 2022
overturned Roe v. Wade
, the 1973 ruling that provided nationwide access to abortion. All have been challenged in court. The Supreme Court
ruled in the case
of Dobbs v. Jackson Women's Health Organization.
U.S. District Court Judge Robert C. Chambers had ruled that the
near-total abortion ban
signed by then-Republican Gov. Jim Justice in September 2022 took precedence over approvals from the U.S. Food and Drug Administration.
'For us to once again federalize the issue of abortion without a clear directive from Congress, right on the heels of Dobbs, would leave us one small step short of defiance,' 4th Circuit Judge J. Harvie Wilkinson III wrote for the court.
'One can of course agree or disagree with the Dobbs decision. But that is not the point,' Wilkinson said. 'At a time when the rule of law is under blunt assault, disregarding the Supreme Court is not an option.'
West Virginia Gov. Patrick Morrisey, who took office in January, had defended challenges to the abortion law when he served as attorney general.
'Big win out of the 4th Circuit today,' Morrisey said in a statement.
GenBioPro Inc., the country's only manufacturer of a generic version of the abortion pill mifepristone, had argued that the state cannot block access to a FDA-approved drug. Chambers had dismissed the majority of GenBioPro's challenges, finding there is 'no disputing that health, medicine, and medical licensure are traditional areas of state authority.'
Appeals judge DeAndrea Gist Benjamin concurred and dissented in part Tuesday, calling it a 'troubling opinion.'
'Put plainly, this law erects barriers to life-saving healthcare for countless West Virginians in ways not envisioned by Congress,' Benjamin wrote.
Not at issue in the appeal was a challenge by GenBioPro concerning a separate West Virginia law that stopped providers from prescribing mifepristone by telehealth. Chambers had allowed that challenge to proceed. The U.S. Supreme Court last year
unanimously preserved access to mifepristone
, which is used in
nearly two-thirds of all abortions
in the U.S. in 2023.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Axios
2 hours ago
- Axios
DHS sends migrants to Eswatini in new 3rd-country deportation
The Trump administration deported five migrants from Cuba, Jamaica, Laos, Vietnam and Yemen to the tiny African nation of Eswatini on Tuesday, the Department of Homeland Security announced. The big picture: The deportation flights came after the Supreme Court last month allowed the administration to resume deportations of migrants to third countries that were not their place of origin. Acting director of Immigration and Customs Enforcement director Todd Lyons said in a memo that such deportations could take place within six hours of notification "in exigent circumstances," the Washington Post first reported this week. However, Lyons said in the July 9 memo that ICE would typically wait 24 hours after informing people that they would be deported. Driving the news: "NEW: a safe third country deportation flight to Eswatini in Southern Africa has landed— This flight took individuals so uniquely barbaric that their home countries refused to take them back," Department of Homeland Security spokeswoman Tricia McLaughlin said on X Tuesday night. They were convicted of a range of crimes that included child rape and murder, according to McLaughlin. The intrigue: It wasn't immediately clear when Trump officials had made a deal with their counterparts in Eswatini to send migrants to the southern African nation or what the terms of any agreement were. Flashback: Following the Supreme Court ruling, eight men from Asia and Latin America who were at the center of the case were deported to South Sudan earlier this month.
San Francisco Chronicle
2 hours ago
- San Francisco Chronicle
Native American radio stations at risk as Congress looks to cut $1B in public broadcasting funding
OMAHA, Neb. (AP) — Dozens of Native American radio stations across the country vital to tribal communities will be at risk of going off the air if Congress cuts more than $1 billion from the Corporation for Public Broadcasting, according to industry leaders. The U.S. Senate is set to vote this week on whether to approve the Department of Government Efficiency's plan to rescind previously approved public broadcasting funding for 2026 and 2027. Fear is growing that most of the 59 tribal radio stations that receive the funding will go dark, depriving isolated populations of news, local events and critical weather alerts. The House already approved the cuts last month. 'For Indian Country in general, 80% of the communities are rural, and their only access to national news, native story sharing, community news, whatever it is, is through PBS stations or public radio,' said Francene Blythe-Lewis, CEO of the Lincoln, Nebraska-based Native American video programming producer Vision Maker Media. 'If the claw back happens, I would say a good 90% of those stations will cease to exist.' Native American communities rely on local radio stations Local radio plays an outsized role in the lives of many who live in Indigenous communities, where cable television and broadband internet access are spotty, at best, and nonexistent for many. That leaves over-the-air TV stations — usually a PBS station — and more often local radio to provide local news, community event details and music by Indigenous artists. Sometimes the news is delivered in Indigenous languages. 'It means we're not going to hear our language on the radio,' Blythe-Lewis said. Flagstaff, Arizona-based Native Public Media, which supports the network of 59 radio stations and three television stations serving tribal nations across the country, said about three dozen of those radio stations that rely heavily on Corporation for Public Broadcasting funding will be the first to go dark if funding is cut for the coming fiscal year that starts Oct. 1. Loris Taylor, CEO of Native Public Media, said in an op-ed that the tribal stations reach more than 1.5 million people and 'may be the only source of locally relevant news, emergency alerts, public safety announcements, language preservation, health information and election coverage.' Republicans face pressure to pass the cuts GOP senators are under pressure from President Donald Trump, who promised last week on his Truth Social platform that any Republican who votes against the cuts 'will not have my support or Endorsement.' Many Republicans say the public media system is politically biased and an unnecessary expense. Sen. Eric Schmitt, a Republican from Missouri, recently defended the cuts as necessary to hack away at the nearly $37 trillion national debt, adding, 'It is critical in restoring trust in government.' But some Republicans have pushed back, such as Maine Sen. Susan Collins, who questioned the proposed cuts last month during a Senate committee hearing. She said that while some of the federal money is assigned to National Public Radio and the Public Broadcasting System, most of it goes to locally owned public radio and television stations. Tribal stations provide lifesaving alerts Jaclyn Sallee is president and CEO of Koahnic Broadcast Corporation and KNBA, its radio station in Anchorage, Alaska. Koahnic produces National Native News, a five-minute daily newscast that features headline news from across Indian Country, and Native America Calling, a daily hourlong call-in program, for about 190 stations across the nation. It also produces Indigefi, a music program in Indigenous languages. KNBA is on Native Public Media's list of those stations that would be most affected by the federal funding cuts — a concern Sallee confirmed, as 40% of the station's funding comes from CPB. 'What we're really worried about are the rural stations in Alaska where they may be the only station in the community,' she said. 'The people that live there depend on the station for vital weather alerts, emergency alerts; it's the local hub of the community where people share information. So that is very troublesome because people's lives are at risk without this service.' It's currently fishing season in Alaska, she said, 'which means getting out in the ocean or in rivers and going long distances to subsist, and so they really rely on weather reports.' Having the news reported in a tribe's language isn't just about preserving that language, she said. Sallee spent summers in Nome with her mother's family. Her grandmother, she said, spoke only Inupiaq. Loss of small stations could hurt the larger system New Mexico PBS's signal reaches all but one of the more than 20 tribes and pueblos in the state. It also has signed an agreement with the Navajo Nation, which has the largest reservation of any tribe in the U.S., that allows the tribe to carry the PBS signal and programming on the Navajo Nation Television network, New Mexico PBS general manger Franz Joachim said. 'It's no question in my mind that, you know, immediately some stations will pretty much go dark,' Joachim said. When those first stations fail, it won't take long for others to follow, Joachim said. And as they do, it will mean fewer and fewer stations left to pay membership dues that also help fund all of the stations. 'So now the whole system starts to fracture,' he said. 'So for me, the federal funding is really about the system as a whole that keeps us in place.' That funding also helps produce national content that groups like Vision Maker Media produce. Those include Native American documentaries shown on PBS like 'Mankiller,' the story of Wilma Mankiller who became the first woman elected principal chief of the Cherokee Nation. Blythe-Lewis compared the potential loss of tribal stations to the country's past attempts to erase Native American cultures, such as through federal boarding schools where Indigenous children were sent for generations to assimilate them into white society and where systemic abuse of Indigenous children was carried out. 'We're erased from public media and therefore invisible and therefore become unknown and unheard of,' she said.
Yahoo
2 hours ago
- Yahoo
Press Release: Sanofi's SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration
Sanofi's SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration Designation earned for a one-time intravitreal gene therapy designed to inhibit two key complement cascade pathways Geographic atrophy is an advanced form of dry age-related macular degeneration, that can lead to permanent vision loss Paris, July 16, 2025. The US Food and Drug Administration (FDA) has granted fast track designation to SAR446597, a one-time intravitreal gene therapy for the treatment of geographic atrophy (GA) due to age-related macular degeneration (AMD). The fast track designation process aims to facilitate the development and expedite the review of medicines to treat serious conditions and fill unmet medical need. The FDA created this process to help deliver important new drugs to patients earlier and it covers a broad range of serious illnesses. SAR446597 delivers genetic material encoding two therapeutic antibody fragments that target and inhibit two critical components of the complement pathway: C1s in the classical pathway and factor Bb in the alternative pathway. This dual-targeting approach potentially offers clinical advantages by providing sustained complement suppression within the retinal microenvironment while significantly reducing treatment burden through elimination of frequent intravitreal injections. The therapy aims to address the underlying pathophysiology of complement-mediated retinal diseases through long-term expression of therapeutic proteins following a single intervention. Sanofi plans to start a phase 1/2 study to evaluate the safety, tolerability, and efficacy of SAR446597. Sanofi is also currently evaluating SAR402663, a one-time intravitreal gene therapy, in a phase 1/2 study (clinical study identifier: NCT06660667), for the treatment of patients with neovascular wet age-related macular degeneration. About age-related macular degeneration and geographic atrophy AMD is an acquired progressive degeneration of the retina that affects approximately 200 million people globally. Geographic atrophy is an advanced form of dry AMD. It is characterized by enlarging irreversible atrophic lesions due to degeneration of retinal cells leading to permanent vision loss in many patients. GA affects approximately 1 million people in the US, more than 2.5 million in Europe, and over 5 million people worldwide and has a profound impact on quality of life, including ability to read, drive and perform other daily activities. About Sanofi in neurologyOur goal is to improve the lives of people with serious neuroinflammatory and neurodegenerative diseases. We are testing the bounds of clinical possibility to research therapies that may address multiple sclerosis (MS), chronic inflammatory demyelinating polyneuropathy (CIDP), Alzheimer's Disease (AD), Parkinson's disease (PD), Age-Related Macular Degeneration (AMD) and other neurological diseases for the people who need them most. Emerging scientific innovations and investments in ophthalmology have the potential to drive a new phase of growth for Sanofi. We are exploring innovative therapies in retinal diseases with unmet need especially where they connect with immune system conditions. About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY Media RelationsSandrine Guendoul | +33 6 25 09 14 25 | Berland | +1 215 432 0234 | Léo Le Bourhis | +33 6 75 06 43 81 | Victor Rouault | +33 6 70 93 71 40 | Timothy Gilbert | +1 516 521 2929 | Ubaldi | +33 6 30 19 66 46 | Investor RelationsThomas Kudsk Larsen |+44 7545 513 693 | Alizé Kaisserian | +33 6 47 04 12 11 | Lauscher | +1 908 612 7239 | Browne | +1 781 249 1766 | Nathalie Pham | +33 7 85 93 30 17 | Elgoutni | +1 617 710 3587 | Thibaud Châtelet | +33 6 80 80 89 90 | Li | +33 6 84 00 90 72 | Sanofi forward-looking statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans' and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Statements' in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi Press Release
